Results 41 to 50 of about 4,912 (206)

Rhinophyma in tuberous sclerosis complex: case report with brief review of literature

open access: yesGMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2014
Tuberous sclerosis or tuberous sclerosis complex (TSC) is an autosomal dominant inherited disease characterized by the triad epilepsy, hamartomas (angiofibroma) and reduced intellectual capacity. Phenotype can vary considerably.
Friedrich, Reinhard E., Hagel, Christian
doaj   +1 more source

Soft Tissue Tumors: Angiofibroma [PDF]

open access: yes, 2013
Review on Soft Tissue Tumors: Angiofibroma, with data on clinics, and the genes ...
Jin, Y, Mertens, F
core   +1 more source

Risk Factors and Characteristics of the Recurrence of Juvenile Nasopharyngeal Angiofibroma: A 22-Year Experience With 123 Cases at a Tertiary Center [PDF]

open access: yesClinical and Experimental Otorhinolaryngology, 2022
Objectives. Despite the efficacy of surgical treatments, the high rate of recurrence in juvenile nasopharyngeal angiofibroma (JNA) after surgery remains an unresolved problem.
Ruihua Fang   +9 more
doaj   +1 more source

Extranasopharyngeal Angiofibroma Originating in the Inferior Turbinate: A Distinct Clinical Entity at an Unusual Site

open access: yesInternational Archives of Otorhinolaryngology, 2014
Introduction The extranasopharyngeal angiofibroma is histologically similar to juvenile nasopharyngeal angiofibroma, differing from the latter in clinical and epidemiologic characteristics. Objectives We present a case of extranasopharyngeal
Marco Antonio Ferraz de Barros Baptista   +2 more
doaj   +1 more source

Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis

open access: yesBiomedicines, 2022
Previous studies have suggested that the topical mechanistic target of rapamycin (mTOR) inhibitors may be effective in treating facial angiofibromas in patients with tuberous sclerosis complex (TSC).
Yu-Ting Lin   +3 more
doaj   +1 more source

A case of inguinal cellular angiofibroma

open access: yesIJU Case Reports, 2020
Introduction Cellular angiofibroma is a benign mesenchymal tumor that is rare and has a good prognosis. However, preoperative distinction of cellular angiofibroma from malignant tumors is difficult.
Rei Kamitani   +7 more
doaj   +1 more source

Polypoidal Lesions in the Nasal Cavity [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2013
Introduction: Nasal polyps are polypoidal masses arising from mucous membranes of nose and paranasal sinuses. They are overgrowths of the mucosa that frequently accompany allergic rhinitis. They are freely movable and nontender.
Kalpana Kumari M.K., Mahadeva K.C.
doaj   +1 more source

Beyond the “3 Ps”: A critical appraisal of the non-endocrine manifestations of multiple endocrine neoplasia type 1

open access: yesFrontiers in Endocrinology, 2022
Multiple endocrine neoplasia type 1 (MEN1), an autosomal-dominantly inherited tumor syndrome, is classically defined by tumors arising from the “3 Ps”: Parathyroids, Pituitary, and the endocrine Pancreas.
Steven G. Waguespack
doaj   +1 more source

Case Report : Cervical Cellular Angiofibroma

open access: yes, 2022
Background: Cellular angiofibroma is a rare benign tumor in the distal genitalia introduced by Nucci et al in 1997 that can occur in both women and men with an age range of 46 – 54 years. In women it usually occurs in the vulva and vagina.
Rakhmah, Nur   +2 more
core   +1 more source

Materials Employed in Preoperative Embolization for Nasopharyngeal Angiofibroma: A Meta-Analysis. [PDF]

open access: yesLaryngoscope
Studies have shown that pre‐surgical embolization improves outcomes for JNA, but the choice of embolization material remains a topic of debate. This study found PVA is the most used material, and that there may be differences in outcomes and complications between embolization materials.
Patel PA   +7 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy